OriCAR-017 for RRMM A top biopharmaceutical company in the clinical stage, Oricell Therapeutics, shared the long-term follow-up results of OriCAR-017, a Phase I study that looked at how well GPRC5D-t...
Results of SATRi-cel therapy CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) has released the latest findings from the investigator-initiated trial CT041-CG4006 (NCT03874897) of satricabt...
NK Cell therapy vs CAR T-Cell therapy The FDA's approval of the first CAR T cell therapy in 2017 was widely celebrated as a significant advancement in cancer treatment. The method enabled a focused a...
What is systemic lupus erythematosus? Systemic lupus erythematosus (SLE) is defined by an abnormal immune response, resulting in a highly varied clinical presentation that can potentially impact many...
SHANGHAI, China, April 30, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and sol...
The future of CAR T-cell therapy: an analysis of its rapid growth and expansion. Within the realm of contemporary medicine, CAR T-cell therapy emerges as an innovative and groundbreaking intervention...
Introduction In the domain of oncology, immunotherapy has emerged as a pioneering methodology, harnessing the body's immune system to combat malignant tumors. There are many immunotherapeutic approac...
Introduction Cytokine Release Syndrome (CRS) is an immune system overreaction triggered by therapies like immunotherapy or CAR-T cell treatment. It prompts an influx of cytokines, causing symptoms ra...
Patients undergoing outpatient CAR T-cell therapy for cancer must be cared for by a multidisciplinary team that includes nurse coordinators, according to a poster presented at the 49th Annual Oncology...
Targeted Therapy in Advanced Cancer: A Precision Approach to Treatment Targeted therapy has significantly transformed the therapeutic options for advanced cancer in the field of oncology. Tar...